Compare First Solar, Inc. (FSLR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs Novartis AG — how do they compare? First Solar, Inc. trades at $227.22 (market cap $25.89B), while Novartis AG trades at $153 (market cap $295.37B). The key difference: Novartis AG is far larger — about 11.4× First Solar, Inc.'s market cap, and Novartis AG pays a 3.07% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals.
| FSLR | NVS | |
|---|---|---|
Market Cap | $25.89B | $295.37B |
Sector | Technology | Health |
52-Week High | $318.30 | $168.62 |
52-Week Low | $180.05 | $119.31 |
Enterprise Value | $24.36B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $239.33, down 4.29% today, with a bullish technical signal from moving averages and a consensus analyst price target of $282.07. The company reported strong revenue growth to $5.22B in 2025, with a net income margin of 32.47%, though it missed Q4 2025 EPS estimates. Recent news highlights multiple class-action lawsuits filed against the company, creating investor uncertainty alongside positive analyst upgrades.
The outlook remains positive due to robust profitability and upward earnings revisions, but risks include legal challenges and potential volatility from overbought technical conditions. Investors should weigh solid fundamentals against near-term sentiment pressures.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
